Figure 1. A 2-week lipid-lowering therapy with atorvastatin reduces vascular endothelial inflammation.

(a) Composite log₂ fold change in brachial vein endothelial inflammatory transcript expression in those randomized to atorvastatin (n = 18¹) or no treatment (n = 10) for 2 weeks. (b) Correlation between atorvastatin-treated patients and composite log₂ fold change in brachial vein endothelial inflammatory transcript expression. (c) Percentage change in LDL-C over 2 weeks¹; colors correspond to <35% or ≥35% reduction in LDL-C. (d) Composite log₂ fold change in brachial vein endothelial inflammatory transcript expression stratified by no treatment (n = 10), <35% reduction in LDL-C (n = 6), and ≥35% reduction in LDL-C (n = 12¹) after atorvastatin treatment.